Nowadays high-dose chemotherapy (HDC) with autologous peripheral blood stem cell transplantation (APBSCT) has a low morbi-mortality.
In this letter, we describe a case of APBSCT in a patient with lung carcinoma following kidney transplantation, 1, 2 who had multiple risk factors for HDC and who successfully completed the procedure without any major complication.
Even though we know that this case is essentially anecdotal and in no way guarantees success in other similar cases, the aim of the letter is to emphasize the value of the pretransplant functional tests and also to indicate that these HDC procedures must be based on several specialized medical disciplines.
The patient was a 57-year-old white male. He was a smoker, obese and hypercholesterolemic, hypertensive, diabetic requiring insulin and with a history of ischemic cardiopathy and aorto-coronary bypass. In May 1996, he received a kidney transplant after being diagnosed with chronic renal failure due to nephrosclerosis. Later in June 1997, he developed a large cell lung carcinoma. He completed three chemotherapy courses with cisplatin and gencitabine. A thoracic scan after treatment showed good response, so we decided to enter the patient in a HDC protocol with peripheral blood stem cell rescue. He was mobilized with G-CSF (16 g/kg/day) s.c. and in two apheresis procedures we collected 12.8 ϫ 10 6 CD34 + cells/kg. The renal and cardiac functions before transplant were normal. As the conditioning regimen for transplantation he received busulphan (4 mg/kg) ϫ 3 days; melphalan (50 mg/m 2 ) ϫ 2 days and thiotepa (125 mg/m 2 ) ϫ 2 days. Transplant-related complications were mucositis grade III and mild liver toxicity. He did not have fever or renal, cardiac or metabolic complications. On day ϩ9 after trans-
Thalidomide for chronic GVHD
Kami et al in their case report of 'Phimosis as a manifestation of chronic GVHD' report that despite intensive immunosuppression there was no improvement in the patient's condition or the phimosis, even though there was some overall improvement in his GVHD. 1 Thalidomide has been found to be beneficial in chronic GVHD by several groups. [2] [3] [4] We have found that, although thalidomide is beneficial in chronic GVHD, it is ineffective in acute GVHD. HDC with ABMT/APBSCT have been used in a small number of patients with non-small cell lung cancer 3 and the results of these studies showed no improvement in survival. 4 In no way are we defending HDC in lung cancer because its role remains experimental up to now. Our message is basically that if pretransplant functional tests and support measures are correct, HDC with APBSCT has a low rate toxicity that increases the inclusion criteria and the number of experimental protocols based on these techniques, whilst limiting the contraindications.
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Centre Thalidomide has also been shown to be an effective treatment for human immunodeficiency virus (HIV) infectionrelated oral ulcers. 7 It would thus be reasonable to assume that thalidomide, because of its known efficacy in the treatment of chronic GVHD and its recognised healing effect on mucocutaneous lesions, might be appropriate therapy in this case.
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